Catégorie : News_Corporate
-
Advanced BioDesign to Present Groundbreaking Research data on AML at the 67th ASH Annual Meeting
Lyon, France – December 5th, 2025 — Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, is proud to announce its participation at the American Society of Hematology (ASH) Annual Meeting 2025 with two significant scientific contributions. Oral Presentation Title: Anthracyclines induce epigenetic changes in ALDH1A that promote chemoresistance…
-
Media Coverage: Advanced BioDesign Featured in Le Figaro: Accelerating Innovation Against Resistant Cancers
Advanced BioDesign is honored to be featured in Le Figaro Économie, which highlights our cutting-edge approach to overcoming cancer resistance through targeted inhibition of ALDH1—a key enzyme that enables tumor survival and relapse. Our lead compound, ABD-3001, currently in Phase 1 clinical trials for acute myeloid leukemia (AML), has shown promising biological activity even at…
-
Advanced BioDesign announces first patient treated under compassionate access for ABD-3001 in relapse and refractory T-cell cell acute lymphoblastic leukemia
Lyon (France), September 4th, 2025 – Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, today announced that the first patient in France has been treated with its lead investigational drug, ABD-3001, under a compassionate access authorization for relapsed and refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL). This treatment…
-
Advanced BioDesign Announces Positive Interim Results from Phase 1 of the ODYSSEY Clinical Trial
Lyon (France), May 27, 2025 – Advanced BioDesign, a clinical-stage biopharmaceutical company specializing in the development of novel therapeutic approaches for resistant cancers, today announced positive interim results from the Safety Review Committee (SRC) for the second part of the Phase 1 ODYSSEY clinical trial. This phase of the study evaluates the tolerance of three…
-
Advanced Biodesign Announces First Patient Dosed in ODYSSEY
Lyon (France), March 4, 2025 – Advanced BioDesign, a clinical-stage pharmaceutical company specializing in the development of new therapeutic approaches to resistant cancers, is pleased to announce that the first patient has been successfully treated for 3 cycles of treatment in the ODYSSEY trial. This trial is designed to evaluate the tolerability of ABD-3001, a…
-
Advanced BioDesign is nominee as « Best StartUp » for 2024 Prix Galien USA
Advanced Biodesign has been nominated as the “Best Start-Up” at the prestigious Prix Galien USA 2024! 🏆 This nomination is a testament to our unwavering commitment to innovation and pushing the boundaries of biotechnology. It reflects the hard work and passion of our entire team in improving health and well-being through cutting-edge biotechnological solutions. Read more…
-
Advanced BioDesign accelerates ODYSSEY clinical trial with a new design following ABD-3001’s highly promising initial results in Acute Myeloid Leukemia
• Initial clinical data for ABD-3001 in AML have led French health authorities to approve a compassionate use program for the treatment. • Thanks to these results, the second part of the First-in-human ODYSSEY study, initially in Phase I, will evaluate the safety and efficacy of ABD-3001 as a monotherapy.
-
Advanced BioDesign announces exceptional first-in-human results for its innovative treatment against Acute Myeloid Leukemia
Lyon (France), June 4, 2024 – Advanced BioDesign, a biotech company specializing in the development of new therapeutic approaches to resistant cancers, has released the first data from its first-in-human ODYSSEY study, aimed at treating acute myeloid leukemia (AML) with the drug candidate ABD-3001. “We are delighted to have demonstrated the good safety and tolerability…
-
Advanced BioDesign joins forces with GTP Bioways to startmanufacturing of its innovative treatment for Acute MyeloidLeukemia (AML)
Lyon, Toulouse (France), March 27, 2024 – Advanced BioDesign, a biotech company specializing in the development of new therapeutic approaches to resistant cancers, and GTP Bioways, a CDMO (ContractDevelopment Manufacturing Organisation) specializing in the anufacture of innovative therapies, today announced their collaboration to meet the crucial needs of the first-in-human ODYSSEY study, aimed at treating…
-
Advanced BioDesign, winner of the France 2030 plan’s call for « i-DEMO » projects to finance its « Odyssey » clinical trial with up to €3M
Advanced BioDesign’s winning project is its first-in-human clinical trial of its drug candidate ABD-3001 for patients with acute myeloid leukaemia (AML) who are resistant to standard treatments.As part of the France 2030 plan, the « i-Demo » scheme supports the development of highly innovative, high added-value products and services to strengthen France’s scientific and technological capabilities. Lyon,…
Advanced BioDesign 